Recessive dystrophic epidermolysis bullosa-generalized other

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

Autosomal recessive dystrophic epidermolysis bullosa generalisata mitis; Autosomal recessive dystrophic epidermolysis bullosa, generalized other; Generalized mitis RDEB; RDEB generalisata mitis; RDEB, non-Hallopeau-Siemens type; RDEB-O; RDEB-generalized other; Recessive dystrophic epidermolysis bullosa, non-Hallopeau-Siemens type; RDEB, generalized intermediate; Recessive dystrophic epidermolysis bullosa, generalized intermediate

Definition[edit]

Recessive dystrophic epidermolysis bullosa (RDEB)-generalized other, also known as RDEB non-Hallopeau-Siemens type, is a subtype of DEB characterized by generalized cutaneous and mucosal blistering that is not associated with severe deformities.

Epidemiology[edit]

  • Its exact prevalence is unknown but this sub-type represents the second most common RDEB, the first one being severe generalized RDEB (RDEB- sev gen).
  • The prevalence of all RDEB sub-types, with the exclusion of RDEB-sev gen, has been estimated at 1/2,040,816 in the United States.

Cause[edit]

  • The disease is caused by mutations within the type VII collagen gene (COL7A1) that lead to an alteration of function or a reduction in the amounts of collagen VII.
  • This impairs collagen VII assembly into anchoring fibrils which anchor the basement membrane to the underlying dermis.
  • This in turn causes reduced skin resistance to minor trauma.

Inheritance[edit]

Autosomal recessive inheritance, a 25% chance

Transmission is autosomal recessive.

Signs and symptoms[edit]

  • Under the term RDEB-other are grouped a spectrum of phenotypes, showing highly variable severity of the cutaneous and mucosal involvement.
  • The disease manifests at birth or during the neonatal period with generalized blistering.
  • Aplasia cutis congenita (congenital absence of the skin) can also be observed at birth.
  • Healing of blisters results in the development of milia, atrophic scarring (less severe than in RDEB- sev gen), dystrophic nails, and, occasionally, albopapuloid lesions (ivory-white colored scar-like papules) and scalp abnormalities.
  • In some patients, the scarring phenomena can lead to a certain degree of pseudosyndactyly and loss of nail plates.
  • Extracutaneous involvement is similar but less severe than in severe generalized RDEB with no hand/foot deformities associated with this disease.
  • Oral cavity lesions and excessive dental caries are common.
  • Patients have a lower risk of esophageal structures and corneal injury than RDEB-sev gen.
  • Growth delay and anemia are uncommon.
  • Genitourinary tract involvement is rare.
  • Patients have an increased risk of developing squamous cell carcinomas (35.8% by age 50 according to the U.S. EB national registry).

Diagnosis[edit]

Treatment[edit]

  • Management is preventive: protective padding of the skin reduces blistering and careful wound care prevents secondary infection and reduces scarring. Oral hygiene is important for management of caries.
  • Nutritional requirements should be evaluated by a dietitian.
  • Esophageal strictures are treated by balloon dilatation with fluoroscopic guidance.
  • A regular follow-up is necessary for the surveillance of SCC.
  • The treatment of SCC is surgical and involves full-thickness excision with wide margins.

Prognosis[edit]

In most cases, life expectancy is normal. However, there is an increased risk of development of metastasizing squamous cell carcinomas with a cumulative risk of mortality of 21.5% by age 55 according to the U.S. EB national registry.




NIH genetic and rare disease info[edit]

Recessive dystrophic epidermolysis bullosa-generalized other is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.